title: Continuous remission in an infant with chest wall malignant rhabdoid tumor after relapse.
abstract: Malignant rhabdoid tumor (MRT) is a highly aggressive tumor that occurs in infancy or childhood. The prognosis, especially in infants, is very poor. Here we report the long-term survival of a 5-month-old boy with MRT that arose from the chest wall. After total resection of the tumor, the patient was given 4 cycles of doxorubicin, vincristine, and cyclophosphamide, alternating with ifosfamide and etoposide. After 18 months off therapy, he had a local recurrence at the same site. After a second total resection, he was given additional chemotherapy with 30.6-Gy local irradiation. No further recurrence has been observed for 5 years since the second complete remission. Currently, he is alive and well at 7.5 years post-onset. Our experience in this case suggests a fundamental strategy of successful treatment of this highly malignant pediatric tumor: (1) complete resection of the localized tumor, (2) intensive multiagent chemotherapy for the minimal disseminated disease, and (3) radiotherapy for local control of the disease.
authors.affiliation: Department of Pediatrics, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. hhosai@koto.kpu-m.ac.jp
authors.forename: Hajime
authors.initials: H
authors.lastname: Hosoi
authors.forename: T
authors.initials: T
authors.lastname: Iehara
authors.forename: K
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: A
authors.initials: A
authors.lastname: Misawa
authors.forename: M
authors.initials: M
authors.lastname: Miyaji
authors.forename: S
authors.initials: S
authors.lastname: Yagyu
authors.forename: M
authors.initials: M
authors.lastname: Koizumi
authors.forename: T
authors.initials: T
authors.lastname: Nishimura
authors.forename: K
authors.initials: K
authors.lastname: Tokiwa
authors.forename: N
authors.initials: N
authors.lastname: Iwai
authors.forename: A
authors.initials: A
authors.lastname: Yanagisawa
authors.forename: T
authors.initials: T
authors.lastname: Sugimoto
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D018335:Rhabdoid Tumor / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D016879:Salvage Therapy; D017741:Survivors; D013899:Thoracic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin; D002945:Cisplatin; D007069:Ifosfamide